Momeson ConviCap(Mometasone Furoate)

Therapeutic Group: Respiratory


Momeson ConviCap: Each capsule contains Mometasone Furoate BP 220 µg inhalation powder.


Mometasone Furoate is a corticosteroid demonstrating anti-inflammatory properties. The precise mechanism of corticosteroid's action on asthma is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g. mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g. histamines, eicosanoids, leukotrienes, and cytokines) involved in inflammation.


Mometasone Furoate is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. It is not indicated for the relief of acute bronchospasm. It is not indicated in children less than 4 years of age.

Dosage & Administration

Recommended Dosages in Patients 4 Years of Age and Older.
1. Previous Therapy: Patients ≥ 12 years who received bronchodilators alone
Recommended Starting Dose-220 µg once daily in the evening
Highest Recommended Daily- 220 µg twice daily or as 440 µg once daily
2. Previous Therapy: Patients ≥ 12 years who received inhaled corticosteroids
Recommended Starting Dose-220 µg once daily
Highest Recommended Daily- 440 µg once daily or 440 µg twice daily.
3. Previous Therapy: Patients ≥ 12 years who received oral corticosteroids
Recommended Starting Dose-4400 µg once daily
Highest Recommended Daily- 440 µg once daily or 440 µg twice daily.

Side Effects

Generally side effects are mild like headache, viral infection, sore throat, nosebleeds and coughing. Systemic and local corticosteroid use may result few side effects like candida infection, immunosuppression, hypercorticism, adrenal suppression, growth effects, glaucoma and cataracts.


Use with caution in active or inactive tuberculosis infection, herpes simplex virus infection of the eye, untreated infections affecting the body as a whole etc.

Use in Pregnancy & Lactation

Pregnancy: There are no adequate and well-controlled studies in pregnant women. Mometasone Furoate, like other corticosteroids should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.
It is not known if Mometasone Furoate is excreted in human milk. Since other corticosteroids are excreted in human milk, caution should be used when Mometasone Furoate is administered to nursing women.

Drug Interaction

Ketoconazole, a strong inhibitor of cytochrome P4503A4 may increase plasma levels of Mometasone Furoate during concomitant dosing.

Over Dose

There are no data available on the effects of acute or chronic over dosage with Mometasone Furoate. Because of low systemic bioavailability and an absence of acute drug-related systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation.


• Protect from light, store in cool & dry place
• Do not store above 30 °C.
• Keep out of the reach of children
• Protect from freezing
• Insert the ConviCap in the ConviHaler just prior to use to protect from deterioration by moisture

Commercial Pack

Momeson ConviCap: Each box contains 5 alu-alu blister strips of 6 capsules.